Skip to main content
Top
Published in: BMC Neurology 1/2020

Open Access 01-12-2020 | Gene Therapy in Oncology | Case report

Case report: discovery of 2 gene variants for aromatic L-amino acid decarboxylase deficiency in 2 African American siblings

Authors: Berrin Monteleone, Keith Hyland

Published in: BMC Neurology | Issue 1/2020

Login to get access

Abstract

Background

Aromatic l-amino acid decarboxylase (AADC) deficiency is a rare genetic disorder with heterogeneous phenotypic spectrum resulting from disease-causing variants in the dopa decarboxylase (DDC) gene. Consensus guidelines recommend dopamine agonists, monoamine oxidase inhibitors, and other symptomatic treatments, but most patients have an unrelenting disease course with no response to these therapies.

Case presentation

We describe 2 African American siblings with AADC deficiency and identify 2 DDC gene variants not previously associated with the disorder. The patients were evaluated for cognitive and neurologic impairments. Diagnosis of AADC deficiency was initially based on evaluation of urine and plasma metabolites, followed by targeted DDC gene sequencing. The first patient, a firstborn African American female, had moderate elevations of vanillactic and vanilpyruvic acids, and slight elevation of N-acetylvanilalanine in urine. The second patient, an African American female and younger sibling of the first patient, had low AADC enzyme activity and elevated 3-O-methyldopa levels in plasma. Genetic testing confirmed that both siblings possessed the same 2 DDC gene variants, which were identified as NM_000790.3: c.48C > A (p.Tyr16Ter) and NM_000790.3: c.116G > C (p.Arg39Pro).

Conclusions

This report describes 2 previously unknown patients with AADC deficiency and confirmed the presence of 2 DDC gene variants not previously associated with this disorder. Further research is needed to identify disease-modifying treatments for this devastating neurometabolic disorder. Gene therapy with a recombinant adeno-associated viral vector serotype 2 carrying the gene for the human AADC protein (AAV2-hAADC) is currently in clinical development.
Literature
1.
go back to reference Atwal PS, Donti TR, Cardon AL, Bacino CA, Sun Q, Emrick L, Reid Sutton V, Elsea SH. Aromatic L-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma. Mol Genet Metab. 2015;115(2–3):91–4.CrossRef Atwal PS, Donti TR, Cardon AL, Bacino CA, Sun Q, Emrick L, Reid Sutton V, Elsea SH. Aromatic L-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma. Mol Genet Metab. 2015;115(2–3):91–4.CrossRef
2.
go back to reference Helman G, Pappa MB, Pearl PL. Widening phenotypic spectrum of AADC deficiency, a disorder of dopamine and serotonin synthesis. JIMD Rep. 2014;17:23–7.CrossRef Helman G, Pappa MB, Pearl PL. Widening phenotypic spectrum of AADC deficiency, a disorder of dopamine and serotonin synthesis. JIMD Rep. 2014;17:23–7.CrossRef
3.
go back to reference Wassenberg T, Molero-Luis M, Jeltsch K, Hoffmann GF, Assmann B, Blau N, Garcia-Cazorla A, Artuch R, Pons R, Pearson TS, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12(1):12.CrossRef Wassenberg T, Molero-Luis M, Jeltsch K, Hoffmann GF, Assmann B, Blau N, Garcia-Cazorla A, Artuch R, Pons R, Pearson TS, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12(1):12.CrossRef
4.
go back to reference Opladen T, Cortes-Saladelafont E, Mastrangelo M, Horvath G, Pons R, Lopez-Laso E, Fernandez-Ramos JA, Honzik T, Pearson T, Friedman J, et al. The international working group on neurotransmitter related disorders (iNTD): a worldwide research project focused on primary and secondary neurotransmitter disorders. Mol Genet Metab Rep. 2016;9:61–6.CrossRef Opladen T, Cortes-Saladelafont E, Mastrangelo M, Horvath G, Pons R, Lopez-Laso E, Fernandez-Ramos JA, Honzik T, Pearson T, Friedman J, et al. The international working group on neurotransmitter related disorders (iNTD): a worldwide research project focused on primary and secondary neurotransmitter disorders. Mol Genet Metab Rep. 2016;9:61–6.CrossRef
5.
go back to reference Shih DF, Hsiao CD, Min MY, Lai WS, Yang CW, Lee WT, Lee SJ. Aromatic L-amino acid decarboxylase (AADC) is crucial for brain development and motor functions. PLoS One. 2013;8(8):e71741.CrossRef Shih DF, Hsiao CD, Min MY, Lai WS, Yang CW, Lee WT, Lee SJ. Aromatic L-amino acid decarboxylase (AADC) is crucial for brain development and motor functions. PLoS One. 2013;8(8):e71741.CrossRef
6.
go back to reference Chien YH, Chen PW, Lee NC, Hsieh WS, Chiu PC, Hwu WL, Tsai FJ, Lin SP, Chu SY, Jong YJ, et al. 3-O-methyldopa levels in newborns: result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Mol Genet Metab. 2016;118(4):259–63.CrossRef Chien YH, Chen PW, Lee NC, Hsieh WS, Chiu PC, Hwu WL, Tsai FJ, Lin SP, Chu SY, Jong YJ, et al. 3-O-methyldopa levels in newborns: result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Mol Genet Metab. 2016;118(4):259–63.CrossRef
7.
go back to reference Whitehead N, Schu M, Erickson SW, Croxford J, Peters M, Hyland K. Estimated prevalence of aromatic L-amino acid decarboxylase (AADC) deficiency in the United States, European Union, and Japan [poster]. In: Presented at: Annual Congress of the European Society for Gene and Cell Therapy: October 16-19, 2018; Lausanne. Whitehead N, Schu M, Erickson SW, Croxford J, Peters M, Hyland K. Estimated prevalence of aromatic L-amino acid decarboxylase (AADC) deficiency in the United States, European Union, and Japan [poster]. In: Presented at: Annual Congress of the European Society for Gene and Cell Therapy: October 16-19, 2018; Lausanne.
8.
go back to reference Hyland K, Reott M: Prevalence of aromatic L-amino acid decarboxylase deficiency in at-risk population [poster]. In: Presented at: Annual Meeting of the American Society of Gene and Cell Therapy: May 16-19, 2018; Chicago. Hyland K, Reott M: Prevalence of aromatic L-amino acid decarboxylase deficiency in at-risk population [poster]. In: Presented at: Annual Meeting of the American Society of Gene and Cell Therapy: May 16-19, 2018; Chicago.
9.
go back to reference Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol. 2003;54(Suppl 6):S49–55.CrossRef Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol. 2003;54(Suppl 6):S49–55.CrossRef
10.
go back to reference Brun L, Ngu LH, Keng WT, Ch'ng GS, Choy YS, Hwu WL, Lee WT, Willemsen MA, Verbeek MM, Wassenberg T, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology. 2010;75(1):64–71.CrossRef Brun L, Ngu LH, Keng WT, Ch'ng GS, Choy YS, Hwu WL, Lee WT, Willemsen MA, Verbeek MM, Wassenberg T, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology. 2010;75(1):64–71.CrossRef
11.
go back to reference Chen PW, Lee NC, Chien YH, Wu JY, Wang PC, Hwu WL. Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clin Chim Acta. 2014;431:19–22.CrossRef Chen PW, Lee NC, Chien YH, Wu JY, Wang PC, Hwu WL. Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clin Chim Acta. 2014;431:19–22.CrossRef
12.
go back to reference Kurian MA, Dale RC. Movement disorders presenting in childhood. Continuum (Minneapolis, Minn). 2016;22(4 Movement Disorders):1159–85. Kurian MA, Dale RC. Movement disorders presenting in childhood. Continuum (Minneapolis, Minn). 2016;22(4 Movement Disorders):1159–85.
13.
go back to reference Kuster A, Arnoux JB, Barth M, Lamireau D, Houcinat N, Goizet C, Doray B, Gobin S, Schiff M, Cano A, et al. Diagnostic approach to neurotransmitter monoamine disorders: experience from clinical, biochemical, and genetic profiles. J Inherit Metab Dis. 2018;41(1):129–39.CrossRef Kuster A, Arnoux JB, Barth M, Lamireau D, Houcinat N, Goizet C, Doray B, Gobin S, Schiff M, Cano A, et al. Diagnostic approach to neurotransmitter monoamine disorders: experience from clinical, biochemical, and genetic profiles. J Inherit Metab Dis. 2018;41(1):129–39.CrossRef
14.
go back to reference Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitter disorders. J Child Neurol. 2007;22(5):606–16.CrossRef Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitter disorders. J Child Neurol. 2007;22(5):606–16.CrossRef
15.
go back to reference Pons R, Ford B, Chiriboga CA, Clayton PT, Hinton V, Hyland K, Sharma R, De Vivo DC. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology. 2004;62(7):1058–65.CrossRef Pons R, Ford B, Chiriboga CA, Clayton PT, Hinton V, Hyland K, Sharma R, De Vivo DC. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology. 2004;62(7):1058–65.CrossRef
16.
go back to reference Arnoux JB, Damaj L, Napuri S, Serre V, Hubert L, Cadoudal M, Simard G, Ceballos I, Christa L, de Lonlay P. Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia. J Clin Endocrinol Metab. 2013;98(11):4279–84.CrossRef Arnoux JB, Damaj L, Napuri S, Serre V, Hubert L, Cadoudal M, Simard G, Ceballos I, Christa L, de Lonlay P. Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia. J Clin Endocrinol Metab. 2013;98(11):4279–84.CrossRef
18.
go back to reference Hyland K, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992;38(12):2405–10.PubMed Hyland K, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992;38(12):2405–10.PubMed
19.
go back to reference Himmelreich N, Montioli R, Bertoldi M, Carducci C, Leuzzi V, Gemperle C, Berner T, Hyland K, Thony B, Hoffmann GF, et al. Aromatic amino acid decarboxylase deficiency: molecular and metabolic basis and therapeutic outlook. Mol Genet Metab. 2019;127(1):12–22.CrossRef Himmelreich N, Montioli R, Bertoldi M, Carducci C, Leuzzi V, Gemperle C, Berner T, Hyland K, Thony B, Hoffmann GF, et al. Aromatic amino acid decarboxylase deficiency: molecular and metabolic basis and therapeutic outlook. Mol Genet Metab. 2019;127(1):12–22.CrossRef
20.
go back to reference Abdenur JE, Abeling N, Specola N, Jorge L, Schenone AB, van Cruchten AC, Chamoles NA. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab. 2006;87(1):48–53.CrossRef Abdenur JE, Abeling N, Specola N, Jorge L, Schenone AB, van Cruchten AC, Chamoles NA. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab. 2006;87(1):48–53.CrossRef
21.
go back to reference Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu S, Byrne BJ, Hwu WL. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. Lancet Child Adolesc Health. 2017;1(4):265–73.CrossRef Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu S, Byrne BJ, Hwu WL. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. Lancet Child Adolesc Health. 2017;1(4):265–73.CrossRef
Metadata
Title
Case report: discovery of 2 gene variants for aromatic L-amino acid decarboxylase deficiency in 2 African American siblings
Authors
Berrin Monteleone
Keith Hyland
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-019-1596-8

Other articles of this Issue 1/2020

BMC Neurology 1/2020 Go to the issue